ArticleJournal of clinical microbiology2016
In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.
Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 58 citations in OpenAlex.
- Nocardia antimicrobial susceptibility testing by microdilution: evaluation of ready-to-use plate including tedizolid and meropenem.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Nontuberculous Mycobacterial Infections at a National Cancer Institute-Designated Comprehensive Cancer Center in Florida.Open forum infectious diseases · 2026Article
- Impact of Imipenem on Cognitive Function, Anxiety-like Behaviour, Neurogenesis, and Astrogliosis in Pentylenetetrazol-Kindled Rats.Antibiotics (Basel, Switzerland) · 2026Article
- Description and complete genome sequence ofFrontiers in microbiology · 2026Article
- Review
- Case Commentary: Another prong of attack? Topical antibiotic instillation with negative pressure wound therapy for nontuberculous mycobacterial skin and soft tissue infections.Antimicrobial agents and chemotherapy · 2023Article
- Manifestations and Management of Trimethoprim/Sulfamethoxazole-Resistant Nocardia otitidiscaviarum Infection.Emerging infectious diseases · 2023Article
- Prosthetic joint infection caused by an imipenem-resistant Mycobacterium senegalense.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Multiple brain abscesses caused byIDCases · 2023Article
- Updated Review onClinical microbiology reviews · 2022Review
- High Rates of Antimicrobial Resistance in Rapidly Growing Mycobacterial Infections in Taiwan.Pathogens (Basel, Switzerland) · 2022Article
- Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1.Antimicrobial agents and chemotherapy · 2022Article
- Epidemiology and Antimicrobial Resistance Profiles of theMicrobiology spectrum · 2022Article
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.Clinical pharmacokinetics · 2021Review
- Multiple brain abscesses due to Nocardia spp. in an immunocompetent patientBiomedica : revista del Instituto Nacional de Salud · 2020Article
- Assessment of VITEK® MS IVD database V3.0 for identification of Nocardia spp. using two culture media and comparing direct smear and protein extraction procedures.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus.Scientific reports · 2020Article
- Zinc Chelator N,N,N',N'-Tetrakis(2-Pyridylmethyl)Ethylenediamine Reduces the Resistance ofInfection and drug resistance · 2020Article
- Invasive Nocardiosis: Disease Presentation, Diagnosis and Treatment - Old Questions, New Answers?Infection and drug resistance · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared the activities of the carbapenems ertapenem, meropenem, and imipenem against 180 isolates of rapidly growing mycobacteria (RGM) and 170 isolates of Nocardia using the Clinical and Laboratory Standards Institute (CLSI) guidelines. A subset of isolates was tested using the Etest. The rate of susceptibility to ertapenem and meropenem was limited and less than that to imipenem for the RGM. Analysis of major and minor discrepancies revealed that >90% of the isolates of Nocardia had higher MICs by the broth microdilution method than by Etest, in contrast to the lower broth microdilution MICs seen for >80% of the RGM. Imipenem remains the most active carbapenem against RGM, including Mycobacterium abscessus subsp. abscessus For Nocardia, imipenem was significantly more active only against Nocardia farcinica Although there may be utility in testing the activities of the newer carbapenems against Nocardia, their activities against the RGM should not be routinely tested. Testing by Etest is not recommended by the CLSI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.